Stammdaten
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
Unternehmen & Branche
| Name | KYNTRA BIO, INC. |
|---|---|
| Ticker | KYNB |
| CIK | 0000921299 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Pharmaceuticals |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 28,8 Mio. USD |
| Beta | 0,90 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 6,440,000 | 183,452,000 | 45.37 | 119,594,000 | -30,038,000 |
| 2025-09-30 | 10-Q | 1,076,000 | 200,636,000 | 49.61 | 137,014,000 | -17,028,000 |
| 2025-06-30 | 10-Q | 1,348,000 | -7,603,000 | -1.88 | 178,055,000 | -222,997,000 |
| 2025-03-31 | 10-Q | 2,739,000 | 4,639,000 | 0.05 | 165,213,000 | -216,896,000 |
| 2024-12-31 | 10-K | 29,621,000 | -47,579,000 | -11.89 | 214,525,000 | -225,602,000 |
| 2024-09-30 | 10-Q | 123,000 | -17,084,000 | -4.25 | 264,421,000 | -243,667,000 |
| 2024-06-30 | 10-Q | 998,000 | -15,544,000 | -3.89 | 293,203,000 | -232,340,000 |
| 2024-03-31 | 10-Q | 25,364,000 | -32,933,000 | -0.33 | 365,868,000 | -228,122,000 |
| 2023-12-31 | 10-K | 46,803,000 | -284,232,000 | -2.92 | 423,529,000 | -204,166,000 |
| 2023-09-30 | 10-Q | 40,134,000 | -63,615,000 | -0.65 | 460,426,000 | -157,169,000 |
| 2023-06-30 | 10-Q | 44,319,000 | -87,680,000 | -0.90 | 515,127,000 | -102,274,000 |
| 2023-03-31 | 10-Q | 36,161,000 | -76,705,000 | -0.81 | 538,544,000 | -48,852,000 |
| 2022-12-31 | 10-K | 140,734,000 | -293,654,000 | -3.14 | 610,087,000 | -21,447,000 |
| 2022-09-30 | 10-Q | 15,735,000 | -91,650,000 | -0.98 | 608,837,000 | 26,306,000 |
| 2022-06-30 | 10-Q | 29,806,000 | -72,624,000 | -0.78 | 686,789,000 | 103,780,000 |
| 2022-03-31 | 10-Q | 60,827,000 | -63,205,000 | -0.68 | 745,934,000 | 158,048,000 |
| 2021-12-31 | 10-K | 235,309,000 | -290,023,000 | -3.14 | 773,821,000 | 209,146,000 |
| 2021-09-30 | 10-Q | 155,973,000 | 49,798,000 | 0.54 | 850,513,000 | 325,792,000 |
| 2021-06-30 | 10-Q | 24,364,000 | -133,988,000 | -1.45 | 808,618,000 | 260,580,000 |
| 2021-03-31 | 10-Q | 38,429,000 | -71,755,000 | 787,301,000 | 371,002,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.